Elanco Inks a $295M Deal with Blackstone for Xdemvy’s Royalties and Milestones, Accelerating Debt Repayment

Shots:Elanco has sold certain future royalties & milestones linked to Xdemvy (0.25% lotilaner ophthalmic solution) for human use, to Blackstone Life Sciences & Blackstone Credit & Insurance to reduce its debt & strengthen its financial positionAs per the deal, Elanco will receive $295M in cash to repay portions of its loans on a…

ByRidhi RastogiMay 7, 2025

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2023

Shots:The US FDA approved 5 NDAs and 2 BLA in July 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 76 novel products in 2023In July 2023, the major highlights drugs were Beyfortus (nirsevimab) approval for the prevention of RSV lower respiratory tract disease in…

BySenior EditorAugust 16, 2023

Elanco Inks a $295M Deal with Blackstone for Xdemvy’s Royalties and Milestones, Accelerating Debt Repayment

Insights+: The US FDA New Drug Approvals in July 2023

Contact US

OUR INFORMATION

FOLLOW US